ESTRO 38 Abstract book

S884 ESTRO 38

Balducci classification, and the G8 score was > 14 in 56.8 %. The distribution according to d’Amico and Zumsteg Score was: low (4 pts), favorable intermediate (10 pts), unfavorable intermediate (28pts) and high risk (53 pts). 91 pts were treated with EBRT and 4pts with Iodine seeds BT. 21 pts previously receive a palliative HT before the decision to propose radiotherapy with a curative intent. HT was used concomitantly with EBRT in 36 pts. Regarding EBRT techniques, a conformational 3D was used for the first 50pts, before the technique moved to IMRT (standard in 10; VMAT in 31 pts). The mean and median dose delivered to the prostate were respectively 69.7 and 74 Gy (Range 24 - 78) to the prostate volume. Pelvic nodes were irradiated in 15 patients. Results The median follow-up time was 5.1 years (CI95%:4.6- 5.9]. EBRT was prematurely stopped in 8 pts because of a grade >=3 acute toxicity in 5 (urinary in 4; diarrhea in 1), a fall at home in 2 and a breakdown in 1 pt. Three patients experienced a grade 3 late toxicity: Bladder in 2 pts; Rectal in 1pt. No grade 4was reported. The median overall survival was 9.9 years. Event Free Survival according to d’Amico and Zumsteg classification are presented in figure 1. Figure 1: Event free survival (death, recurrence) according to D’Amico/Zumsteg classification 1: Low and Favorable Intermediate risk ; 2: Unfavorable Intermediate risk; 3: High risk Conclusion Radiotherapy with a curative intent may be proposed in selected patients of 80 years or more, providing an accurate geriatric oncology evaluation to evaluate the benefit of this treatment in term of overall survival and quality of life. EP-1642 Short-course accelerated palliative EBRT for advanced head and neck cancer in elderly patients M. Ferro 1 , G. Macchia 1 , S. Cilla 2 , A. Ianiro 2 , V. Picardi 1 , M. Boccardi 1 , E. Arena 1 , M. Ferro 1 , S. Cammelli 3 , F. Romani 4 , S. Riga 4 , E. Farina 3,5 , M. Buwenge 3 , M.A. Sumon 6 , A. Kamal Uddin 6 , P. Assalone 7 , V. Valentini 8 , A.G. Morganti 3 , F. Deodato 1 1 Fondazione di Ricerca e Cura “Giovanni Paolo II”, Radiotherapy Unit, Campobasso, Italy ; 2 Fondazione di Ricerca e Cura “Giovanni Paolo II”, Medical Physics Unit, Campobasso, Italy ; 3 Dept. of Experimental- Diagnostic and Specialty Medicine – DIMES- S.Orsola-Malpighi Hospital, Radiation Oncology Center, Bologna, Italy ; 4 Dept. of Experimental- Diagnostic and Specialty Medicine – DIMES- S.Orsola-Malpighi Hospital, Medical Physics Unit, Bologna, Italy ; 5 Maria Cecilia Hospital- GVM Care & Research, Radiation Oncology Unit, Cotignola RA, Italy ; 6 United Hospital Limited- Gulshan, Radiation Oncology Department, Dhaka, Bangladesh ; 7 Veneziale Hospital, Oncology Unit, Isernia, Italy ; 8 Policlinico Universitario “A. Gemelli”- Università Cattolica del Sacro Cuore, Department of Radiotherapy, Roma, Italy Purpose or Objective To assess the safety and efficacy of a SHort-course Accelerated RadiatiON therapy (SHARON) regimen in the

(Tomotherapy®, Accuray, Wisconsin) and daily IGRT (MVCT). Patients’ characteristics are reported in Table 1. Median ( range) age at diagnosis 82 (80-90) years Median (range) iPSA 10.09 (3.74-300.0) ng/ml

6: 7: 8:

9

11

Median ( range) Gleason Score

6

9: 9

cT1c: cT2a: cT2b: cT2c: cT3: cT4: 1

16

3 2

T Stage

10

2

Results Median follow up was 61 (13.3-128.6) months. Acute and late toxicity were mild, with only one late G3 rectal toxicity (2.94%) registered, eventually solved by Argon Plasma applications, and 1 G3 urinary stenosis (2.94%), solved with temporary catheterization. Late G2 toxicity were 14.7% (5 pts) for urinary tract and 5.88% (2 pts) for the rectum. Five-year biochemical relapse-free survival (bRFS) was 73.5% (25/34 pts) and clinical relapse-free survival was 79.4% (27/34 pts). Median bRFS and distant progression- free survival (calculated from the last day of RT) were 56.3 and 61.1 months respectively Eighteen pts were dead at the last follow up, six of whom with a prostate cancer Radical radiotherapy with a curative intent even in elderly pts demonstrated good results in terms of both biochemical control and progression-free survival, with a good toxicity profile. In our opinion, radical treatment in elderly pts could improve their life expectation and quality of life. EP-1641 Radiotherapy for prostate cancer patients over 80 years: 95 patients treated in a single institution P. Méré 1 , C. Dalban 2 , E. Peynet 2 , A. Guignot 1 , J. Droz 3 , P. Pommier 1 1 Centre Léon Bérard, Department of Radiation Oncology, Lyon, France ; 2 Centre Léon Bérard, Department of Research and Innovation, Lyon, France ; 3 Centre Léon Bérard, Department of Medical Oncology, Lyon, France Purpose or Objective The benefit of radiotherapy alone or associated with hormonal treatment is still debated in men aged 80 years or more, due to competitive risk of death and the fear to induce more often severe acute or late toxicities than younger men. The objectives were to assess if the standard of care could be applied in that population Material and Methods A retrospective study has been conducted in all consecutive patients (pts) aged 80 years or more, treated with a curative intent from January 2003 to December 2013 in a single radiotherapy center for a non-metastatic prostate adenocarcinoma (prostatectomy excluded). All patients received external beam radiotherapy (EBRT) or brachytherapy (BT) with or without associated hormonal therapy (HT) according to the cancer status, co- morbidities, and physician decision. 95 pts aged from 80 à 91 Years (median 81.9 Years) have been included. The majority of patients (92.2%) were in the 80 to 85 years age group. The Performance Status was 0 in 84% and 1 in 16%. The majority of patients had 1 or 2 co-morbidities, but most were rated CIRS-G-1 or 2 and therefore not severe. All patients had an assessment of their overall health based on medical record data according to Balducci classification and G8 oncoding and item distribution. 83.2% were considered as “fit elderly” according to progression. Conclusion